Phase 3 Readout~month

Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability

Name: Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability
Start: 2029-09-30

September 30, 2029

Company: BioLineRx Ltd. (BLRX)
Indication: Multiple Myeloma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability — BLRX Phase 3 Readout | BioSniper